|
MechanismDNA polymerase III inhibitors [+2] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date18 Apr 1991 |
A Phase 1, single-center, randomized, double-blind, placebo-controlled, incomplete block, 3-period crossover, single-dose escalation study to determine the safety, tolerability and pharmacokinetics of orally administered SAR442168 tablet in healthy East Asian (Japanese / Chinese / Korean) male subjects
Retrospective chart review study to evaluate mobilization effectiveness of G CSF+plerixafor or G-CSF+/-chemotherapy for the first mobilization attempt in patients with multiple myeloma
BART: Benefits of Adding Rapid-acting insulin(s) in patients with diabetes currently uncontrolled on basal insulin Therapy: A prospective observational study in Korea.
100 Clinical Results associated with Sanofi-Aventis Korea Co., Ltd.
0 Patents (Medical) associated with Sanofi-Aventis Korea Co., Ltd.
100 Deals associated with Sanofi-Aventis Korea Co., Ltd.
100 Translational Medicine associated with Sanofi-Aventis Korea Co., Ltd.